Prior antibiotics exposure predicts early and prolonged CD19 CAR T-cell-related hematologic toxicity and prognosis in acute B-cell leukemia - Takeaways - MDSpire

Prior antibiotics exposure predicts early and prolonged CD19 CAR T-cell-related hematologic toxicity and prognosis in acute B-cell leukemia

  • By

  • Jiachen Liu

  • Yingying Li

  • Feng Zhu

  • Bin Lv

  • Jia Xu

  • Mengyi Du

  • Kailin Xu

  • Heng Mei

  • April 7, 2025

  • 0 min

Share

  • 1

    Prior antibiotic exposure, particularly high-frequency antibiotics, significantly correlates with severe early hematologic toxicity in R/R B-ALL patients receiving CAR-T therapy.

  • 2

    A novel antibiotic-based score model was developed to predict early hematologic toxicity, demonstrating higher sensitivity and specificity than existing models.

  • 3

    Patients categorized as high-risk (score ≥3) exhibited poorer clinical outcomes, including shorter median progression-free survival and overall survival.

  • 4

    External validation confirmed the model's robustness, showing consistent results in predicting severe hematologic toxicity across different patient cohorts.

  • 5

    The model's focus on high-frequency antibiotic exposure and tumor burden enhances its utility in identifying patients at risk for CAR-T cell related hematologic toxicity.

Original Source(s)

Prior antibiotics exposure predicts early and prolonged CD19 CAR T-cell-related hematologic toxicity and prognosis in acute B-cell leukemia

  • by Jiachen Liu, Yingying Li, Feng Zhu, Bin Lv, Jia Xu, Mengyi Du, Kailin Xu, Heng Mei

  • April 7, 2025

Related Content

Fistulizing Crohn's disease

Luca Stocchi, M.D., a colorectal surgeon at Mayo Clinic in Florida, presents a surgical case involving a 53-year-old male with long-standing, fistulizing Crohn's disease. The patient had a prior open ileocolic resection and subsequently developed progressive weight loss and anemia.

  • January 5, 2026

  • 1 min
Assessment of Clinical Complications and Treatment Approaches in Non-Transfusion-Dependent α- and β-Thalassemia Patients Compared to Matched Controls: A Retrospective Analysis Utilizing Administrative Claims Data in the United States

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.

  • by

  • December 17, 2025

  • 4 min